Cergutuzumab amunaleukin

Drug Profile

Cergutuzumab amunaleukin

Alternative Names: CEA-IL2v; RG-7813; RO-6895882

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Class Antineoplastics; Immunoglobulins; Interleukins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Carcinoembryonic antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 07 Oct 2016 Pharmacokinetics data from a phase I trial in Solid tumours (Late-stage disease) presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 01 Aug 2016 Roche completes a phase I trial in Solid tumours (Late-stage disease) in USA, Denmark, Finland, France, Netherlands, Spain, Switzerland and the UK (NCT02004106)
  • 16 Apr 2016 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top